Introduction
Normal tissue development and maintenance are dependent on a population of stem cells that can reproduce indefinitely and differentiate into one or more cell types. In the setting of tissue regeneration, enhancing progression through the cell cycle is an attractive means for the cellular expansion necessary to repopulate or develop de novo a replacement tissue. 1, 2 Conversely, cancer is a disease of dysregulated cellular expansion that can be limited by blocking cell cycle progression. 3 The cell cycle is governed by the coordinated activation and deactivation of a heterodimeric family of serine/threonine protein kinases composed of a catalytic cyclin-dependent kinase (CDK) subunit and a regulatory cyclin subunit. 4, 5 CDK activity relies on the presence of a specific cyclin, the expression of which fluctuates during cell cycle progression. Antiproliferative signals can block CDK activity by inducing the expression of two families of cyclin-dependent kinase inhibitors (CKIs) that can bind CDKs or CDK/cyclin dimers directly, inhibiting their kinase activity. 4 In addition, genotoxic stress sensed by the ataxia telangiectasia-mutated/related pathway can regulate CDK activity via CKIs or post-translational modification of the target CDK itself. 6, 7 Thus, the transduction and amplification of pro-and antiproliferative signals from within and outside the cell occurs at the level of the CDK/cyclin complex, highlighting their potency as potential therapeutic targets. This review will outline the function of CKIs in the cell cycle of normal and tumor stem cells, and the development of targeted interventions to enhance or restrict movement through the cell cycle.
Adult stem cells and the cell cycle
Homeostasis within adult stem cell compartments is characterized by a quiescent stem cell pool intermittently yielding daughter cells via mitosis into an amplifying pool of progenitor cells with a high proliferative capacity. The rate of hematopoietic stem cell (HSC) cycling in small rodents was estimated at 30 days by 5-bromodeoxyuridine (BrdU) labeling 8 and up to 1 year in nonhuman primates. 9 Similar cycling kinetics have also been observed in other stem cell types such as mouse cornea epithelia 10 and hair follicles. 11 In the skin, four times as many dermal stem cells are in the S-G 2 /M phases of the cell cycle as compared to more primitive dermal cells. 12 In the central nervous system, quiescent neural stem cells (NSCs) quickly proliferate in response to ischemic injury in an attempt to repair damaged tissue. 13, 14 This quiescent phenotype necessary to prevent premature exhaustion of the repopulating ability of adult stem cells over the lifetime of individual, in coordination with a rapidly dividing progenitor pool responsive to stress conditions, including tissue damage and transplantation, is a fundamental characteristic of tissue stem cells.
Manipulation of adult stem cells for purposes of gene targeting and subsequent transplantation is limited by their quiescence. The ability to expand HSCs, the only defined stem cell population with current therapeutic applications, with cytokine stimulation is limited and associated with concomitant differentiation and loss of the primitive stem cell phenotype. 15, 16 Therefore, alternative strategies to expand stem cells are ultimately required to generate a stem cell population sufficient to repopulate a diseased tissue or generate a tissue replacement ex vivo. The cell cycle profile of stem cells is characterized by a predominance of cells in G 0 /G 1 , and as such removal of the inhibition of progression through G 1 has been thought to be a rational approach to expand stem cells ex vivo. 17 Progression through G 1 is governed by the pRb pathway. 18 Following cell division and in the presence of mitogenic signals, cells upregulate D-type cyclin expression. The D-type cyclins can then interact with CDK4 and/ or CDK6 that phosphorylate members of the retinoblastoma family of proteins, including pRb, p107 and p130. Complete phosphorylation of pRb causes E2F disassociation and transcription of genes necessary for DNA replication during the synthesis (S) phase of the cell cycle.
Progression into S phase is delayed by the action of two classes of CKIs, the CIP/KIP family p21 19, 20 In contrast, the CIP/KIP CKIs induce G 1 arrest by inhibiting cyclin A/CDK2 and cyclin E/cdk2 at higher concentrations, despite predominantly promoting cyclin D/CDK4 assembly at lower concentrations. 21 The CKIs act as molecular brakes to progression through G 1 and are potential targets for normal and cancer stem cell therapies.
The CIP/KIP CKIs and adult stem cells p21 Studies of CKIs in adult stem cells have largely employed murine knockout models (Table 1 ) or molecular targeting of the CKI in a highly enriched stem cell population. The first identified mammalian member of the CIP/KIP family, p21, was discovered based on its association with multiple cyclins and CDKs. 33, 34 p21 knockout mice do not show overt deficits in hematopoiesis, however there is increased cycling within the HSC compartment as evidenced by a smaller fraction of HSCs in G 0 and an increase in hematopoietic failure following treatment with the S-phase toxin 5-fluorouracil. 29 Moreover, serial bone marrow transplantation in a 129/SV background revealed complete loss of p21 À/À HSC repopulating ability following five serial transplantations as compared to 50% survival of wild-type bone marrow recipients. 29 Knockdown of p21 in the human HSC-enriched CD34 + CDD38 À population via a lentiviral vector resulted in increased HSC numbers ex vivo and an enhanced repopulating ability when transplanted into nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. 35 In CD34 + -enriched human HSCs, transient or stable knockdown of p21 by short, interfering RNAs (siRNAs) increased transduction efficiency and integration of a lentiviral vector without functional loss following transplantation into NOD/ SCID mice. 36 Murine p21 À/À HSCs transduced with HoxB4 expanded 2-to 3-fold more in vitro and showed increased engraftment in a manner dependent on the length of time in culture as compared to HoxB4-transduced wild-type HSCs. 37 The role of p21 in HSCs has been reexamined recently in the C57BL/6 mouse strain where loss of p21 did not affect HSCs under homeostatic conditions but resulted in a fourfold reduction in repopulating ability following 2 Gy irradiation, 38 suggesting a strain-dependent effect of p21. Taken together, these results indicate that in the hematopoietic system, temporary targeting of p21 alone or in combination with other manipulations can increase engraftment following transplantation whereas permanent removal of p21 may result in a loss of HSC functionality over the course of long-term engraftment or serial transplantation. Normal development 28 Increased proliferation with ultimate exhaustion 29 No increase in spontaneous or induced tumors p27
Kip1
Gigantism, organomegaly 30 Increased progenitor cycling 31 Pituitary adenomas and induced tumors p57
Kip2
Developmental defects involving muscle, bone, cartilage and retina 32 
NA
Beckwith-Wiedemann syndrome in humans, increased childhood cancers Abbreviations: HSC, hematopoietic stem cell; NA, not assessed. Although all CKIs can limit cell cycling to some degree, the results of the knockout studies highlight the cell-specific nature of these affects and other potential roles of the CKIs apart from the cell cycle.
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The role of p21 has been defined in other adult stem cell populations. Endothelial progenitor cells in a p21 heterozygous background showed increased colonyforming units in vitro and neovascularization in a disk angiogenesis model in vivo. 39 However, complete loss of p21 resulted in an increased sensitivity to apoptotic stimuli and larger degrees of cell death at areas of neovascularization. 39 In two other stem cell systems complete loss of p21 is associated with decreased proliferation in response to tissue injury. Enterocytes in p21 knockout mice showed decreased proliferation in response to small bowel resection as compared to wildtype or p27 knockout mice, without a block in differentiation. 40 Similarly, p21 knockout mice exhibited decreased skeletal muscle regeneration following cardiotoxin-induced injury. 41 In the latter, although increased proliferation as evidenced by proliferating cell nuclear antigen (PCNA) staining was observed, there was a coincident increase in apoptosis and an observed deficit in myogenic progenitor cell differentiation into myotubes in culture. 41 p21 also regulates NSCs in the mammalian brain. p21 knockout mice have increased NSCs in the forebrain up to 8 months of age as compared to wild-type mice but thereafter p21-null NSCs decrease in number such that at 16 months the NSC population is less than that in wildtype mice. This decline is associated with loss of the ability to label the cells with BrdU in vivo and in vitro and generate neurospheres in culture suggestive of a proliferative defect in p21 knockout NSCs as compared to wild-type cells. 42 Following middle cerebral artery occlusion there was an increase in activation of neural precursor cells in the hippocampus and subventricular zones of 8-to 12-week-old p21 À/À mice as measured by BrdU incorporation and expression of the neural migration marker DCX. 43 This increased activation was not observed in a p53 À/À background or as a result of differences in the neural mitogen FGF-2, further defining a cell intrinsic effect of p21 on neural precursor cells. 43 Intrinsic and extrinsic regulators of stem cells have also been shown to mediate their affect at least partially through p21. The zinc-finger transcription repressor Gfi-1 restricts HSC proliferation and its loss inhibits engraftment in the setting of competitive bone marrow transplantation in association with decreased p21 expression as compared to wild-type HSCs. 44 Forced expression of b-catenin, a downstream mediator of Wnt signaling, generated hematopoietic failure with a block of myeloid lineage commitment, lymphoid development and stem cell repopulating ability, and was associated with decreased expression of p21. 45 Notch signaling has been shown to delay human cord blood-derived CD34 + cell differentiation with a loss of cells in G 0 /G 1 of the cell cycle 46 possibly through degradation of both p21 and p27 via skp2-mediated proteasome targeting. 47 In the absence of telomerase, p21 enhances cell cycle progression in intestinal progenitor cells and the repopulating ability of HSCs without affecting the telomere length or increasing the rate of chromosomal instability in these cells. 48 A recent study also demonstrated p21, not p16, as a mediator of Bmi-1 activity in NSCs from fetal neural tissue. 49 The emerging paradigm of p21's role in adult stem cells is maintenance of the stem cell phenotype by limiting cell cycling. Loss of p21 may initially expand the stem cell population but sustained loss may lead to decline in stem cell number or functionality under conditions of stress.
p27
Unlike the expansion of HSCs in the absence of p21, loss of p27 leads to expansion of the hematopoietic progenitor population as evidenced by increased colony-forming cells without concomitant increases in stem cell number, proliferation or self-renewal. 31 However, p27 À/À bone marrow cells became the dominant hematopoietic cell population following competitive transplantation with wild-type cells. 31 Therefore targeting p27 may allow for generation of a functionally enhanced differentiated cell phenotype without alteration of stem cell abundance or characteristics. Similar results were observed in the murine brain, where the number of neural progenitor cells, and not NSCs, in the subventricular zone was increased in the absence of p27. 50 Targeting p27 by antisense oligonucleotides in combination with neutralization of transforming growth factor-b signaling enhances retroviral transduction of human CD34 + cells, 51 presumably by two independent mechanisms.
52
In addition, the combined loss of p27 and the MYC antagonist MAD1 increased HSC frequency in the bone marrow and enhanced repopulating ability as compared to wild-type bone marrow cells. 53 Loss of p27 in the retinal progenitor compartment in mice leads to an increase in both mitosis and apoptosis during development and enhances the regenerative ability of liver progenitor cells. 54 Most recently a mutant p27 knock-in unable to bind to CDK/cyclin complexes was shown to expand stem and progenitor cell populations as well as generate a wide range of tumors.
55 p27 appears to be a progenitor-specific CKI regulating expansion of an intermediate cell phenotype without alterations in more primitive cell numbers or function, however given the results of the recent p27 knock-in model 55 further studies of p27 in adult stem cells are warranted.
p57
In contrast to p21 and p27, little is known regarding the role of p57 in adult stem cell populations. While it has been shown that p57 mRNA is highly expressed in an HSC-enriched side population of c-kit + Sca-1 + Lineage À (KSL) bone marrow cells that efflux Hoescht dye, the functional role of p57 in these cells has not been definitively determined. 56 p57 also appears to be unique to freshly isolated CD34 À KSL cells with respect to the other CIP/KIP family members p21 and p27. 57 However, p57 expression was immediately lost following treatment with cytokines and was dependent on lipid raft clustering in the membrane as this downregulation was inhibited by b-cyclodextrin. 57 Moreover, p57 loss appeared to correlate with activation of the AKT-FOXO pathway.
57 p57 has been shown to regulate pancreatic progenitor cell cycling, as loss of p57 leads to increased cycling but not overall expansion due to a coincident increase in apoptosis. 58 The myogenic factor MyoD induces p57 in the absence of p21 in C2.7 mouse myoblasts. 59 The INK4 CKIs and adult stem cells with the D-type cyclins. 60 Knockout models of p18 and p16 have been employed to determine their roles in adult stem cell populations. p18 knockout mice have increased HSC 26 and bronchioaveolar progenitor 61 pools as compared to wild-type mice, and p18-null HSCs show an engraftment advantage over wild-type HSCs in the setting of competitive bone marrow transplantation. 26 Thus, p18 loss results in expansion of a primitive HSC with the ability to self-renew over the long-term with maintenance of functionality. Moreover loss of p18 appears to have enhanced repopulating ability and increased stem cell numbers, with respect to stem cell expansion achieved with either p21 or p27 loss, respectively. p18 has also been shown to be significantly downregulated in fetal-derived HSCs as compared to those from adults 62 and could explain their increased regenerative ability following transplantation into irradiated hosts.
HSC functionality is maintained following cellular proliferation in the absence p18. HSCs from a p18-null background were able to compete with freshly isolated HSCs for engraftment in irradiated hosts following tertiary serial transplantation. 26 Accelerated exhaustion of HSCs as a result of permanent loss of p21 was overcome by knockout of p18, allowing sustained engraftment following three competitive bone marrow transplants. 63 Interestingly, p18 and p21 appear to have opposite effects on the long-term durability of HSCs in the serial transfer model in that either molecule limits HSC proliferation but p21 loss also decreases the functionality of the resultant daughter cells. This data suggest p18 as a potential target for countering stem cell aging with maintenance of the stem cell phenotype necessary for functional engraftment over the lifetime of the individual. p16 p16 has recently been implicated in modulating aging in both HSCs and NSCs. In the former, p16 expression increases with age and limits both HSC number and the competitive repopulating unit of mice older than 56 weeks, but not mice 8-12 weeks old. This increased repopulating ability occurred in the setting of increased cycling and resistance to apoptosis, as well as upregulation of HES1, a major downstream mediator of Notch signaling that also has been shown to regulate both p21 and p27. 23 p16 deficiency also limits the decline in neural multipotent progenitor numbers and self-renewal ability in the mice over 2 years of age as compared to 3 monthold mice as well as neurogenesis in the mouse olfactory bulb. 64 Thus, targeting p16 may be used to enhance the functionality of aged stem cells.
Cancer stem cells and CKIs
In as much as a tumor is a heterogeneous yet clonal tissue with regenerative capacity, it has been hypothesized that a population of tumor-initiating cells exists with properties, namely self-renewal and multipotentiality, homologous to those of normal stem cells. 65 These cancer stem cells were first isolated from acute myelogenous leukemia 66 and have since been identified in tumors of the breast, 67 prostate 68 and brain. 69 Whether these cancer stem cells arise from normal stem cells that acquire a more proliferative phenotype or normal progenitor cells that have a high proliferative capacity and then gain the ability to self-renew is likely tumortype dependent and open to debate; leukemic stem cells giving rise to AML in NOD/SCID mice can have variable self-renewal potential suggestive of a different cell of origin. 70 However the shared characteristics of multidrug transporters, a quiescent phenotype, and high repopulating frequency may help explain the inability of traditional chemoradiation therapies to completely eradicate a tumor. 71 Targeting the molecules responsible for the quiescent phenotype may have a twofold effect on the efficacy of antitumor therapies. The toxicity of most traditional chemotherapeutic agents as well as radiation is dependent on the phase of the cell cycle. Therefore, increasing the rate at which cancer stem cells progress through the cell cycle should increase the probability of exposure of these cells to therapeutic doses of the anticancer agents providing an argument for combination therapies that include targeting a CKI and a traditional chemotherapeutic agent. Second, it has been shown that knockout of p21 leads to exhaustion of normal stem cells following serial transplantation 29 and p27 limits proliferation of the hematopoietic progenitor compartment. 31 The overlapping features of normal and cancer stem cells suggest that exhaustion of the cancer stem cell self-renewal capacity may ultimately lead to loss of the driving force behind the tumor itself, however, targeting of a CKI in a defined cancer stem cell population has not been studied.
Definition of the cell cycle regulation in cancer stem cells is also lacking. Mutations in the CIP/KIP family of CKIs themselves are exceedingly rare in human tumor samples or cell lines. However, as these molecules are downstream of a number of known tumor suppressors or oncogenes, genomic alterations may not be observed and altered protein expression levels may result from lesions in upstream signaling molecules. The INK4 members p14 ARF , p15 and p16 are defined tumor suppressors in humans. The clonality of the cells harboring these mutations and their transplantability, two key features of stem cells, is unknown. Therefore, the possibility exists that given that the bulk of the tumor is not of a cancer stem cell phenotype, these genomic lesions may not be representative of the cancer stem cell itself and may have arisen during proliferation or in a distinct, yet dominant, subset of cells in the tumor.
The best evidence for the roles of CKIs in cancer stem cells comes from knockout mice (Table 1) in which the CKI is known to be lost in the tumor-initiating cell. According to this paradigm, the INK4 proteins p16, p15 and p18 and the CIP/KIP members p27 and p57 have been shown to be tumor suppressors. p16 knockout mice develop a range of tumors in different organs 22 whereas p15 mice have a low incidence of angiosarcomas. 24 Both p18 and p27 are haploinsufficient tumor suppressors in the presence of carcinogens and absence of either CKI leads to an increase incidence of spontaneous pituitary tumors. [72] [73] [74] Our own study showed an increase in T-cell leukemia following serial transplantation of p18
HSCs that was derived from a CD3 lo tumor-initiating cell, not an immunophenotypically defined HSC, and was associated with hypermethylation of the p15 and/or p16 promoters. 75 This study supports the notion that tumor-initiating cells or tumor stem cells may not be
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Targeting CKIs in normal and cancer stem cells INK4 family and structural basis for therapeutics p15 and p16 share 80% sequence identity with each other while p18 and p19 share 40-45% identity with each other and with p16 and consist of four (p15 and p16) or five (p18 and p19) ankyrin repeats, a common helix-turnhelix structural motif approximately 33 amino acids in length that mediates protein-protein interactions. 77 The tertiary structure is stabilized by hydrophobic interactions between neighboring a-helices. Mutations of the residues important for this stabilization lead to loss of structure and protein aggregation, and have been found in human tumors (Figure 1) . 78 Therefore, the potential exists for small molecule or gene therapy to stabilize the tertiary structure of the target INK4 family member, thereby restoring its function.
The third ankyrin repeat and N terminus of the fourth repeat are the core element of the INK4 family necessary to bind cdk4 or cdk6. 79 Mutations of the residues involved in this interaction block the INK4 inhibition of CDK activity and have been identified in tumor samples. 79 By immunoprecipitation and kinase activity experiments, p18 has been shown to preferentially interact with cdk6 as compared to cdk4. 79, 80 However, double knockout mice for p18 and cdk4 exhibit the hypocellularity characteristic of cdk4 knockouts rather than the hyperproliferative phenotype of the single p18 knockout. 81 This suggests that p18 is fully dependent on CDK4, but it does not definitively prove the case in stem cells. A 20 amino-acid polypeptide of residues 83-104 of p16 has been shown to bind and inhibit CDK4 in vivo. 82 This suggests that alternatively, a small peptide of cdk4 could potentially bind p18 and block its interaction with full-length CDKs. A small molecule inhibitor of p18 should either be targeted to disrupt the tertiary structure of the molecule or directly inhibit its association with cdk4 and cdk6 by mimicking p18's binding pocket on cdk4 and cdk6.
Gene therapy approaches to the CIP/KIP family
Targeting the CIP/KIP family members via a small molecule may be conceptually more difficult than the INK4 family due to their existence in solution as inherently unstructured proteins that assume a higher ordered structure following association with a cyclin/ CDK complex. All three family members contain a homologous CDK-binding domain in their N terminus that in isolation can inhibit CDK activity and a nuclear localization signal in the C terminus (reviewed by Mainprize et al. 83 ). p21 alone has a PCNA-binding domain, while p27 and p57 have a QT domain in their C terminus. p21 appears to have opposing roles within the cell, perhaps dependent on its subcellular localization. As a cytosolic protein, p21 can promote the formation of CDK/cyclin complexes; its expression is upregulated following mitogen treatment in some cell lines and has been shown to be a target of the PI3K, a known inducer of cell cycle progression. As a nuclear protein, p21 is free to inhibit DNA polymerase-d through its sequestration of PCNA. Similarly p27 can have both pro-and antiproliferative functions depending on the signaling pathway in which it functions. For example, p27 +/À heterozygous mice are more susceptible to breast or prostate tumors than p27-null mice. 84, 85 p21-null mice show enhanced breast tumor progression after overexpression of Ras but not Myc. 86 Contrary to the assumption of p21 as a tumor suppressor, its overexpression is associated with a poor prognosis in breast cancer while decreased levels of p27 in breast, bladder, lung as well as other tumors confer a poor prognosis. 87 Taken together this data demonstrate both tissue-specific and pathway-dependent roles for p21 and p27 and potential therapies targeted to these molecules must take CDK inhibitors in stem cells MJ Boyer and T Cheng into account these roles outside the cell cycle or in the context of dysregulation of other molecular pathways. Given the relationship between normal and cancer stem cells discussed above, alteration of p21 or p27 levels may confer a selective advantage and thus targeting these molecules within specific tumor types may be an efficacious chemotherapeutic approach.
Besides the reports on human HSC manipulations, 35, 36 several additional studies have demonstrated the effectiveness of an antisense approach to knockdown p21 expression in other tissue types or cancer cells. In both a rat vascular smooth muscle cell line and the human breast cancer cell lines T47D and MCF7 antisense oligonucleotides directed to p21 limited cellular growth or induced apoptosis. 88, 89 p21 antisense treatment also sensitized HCT116 human colon cancer cells to irradiation 90 and Bcap37 breast cancer cells to paclitaxel plus 5-fluorouracil. 91 It is presumed that the combination of p53 upregulation in combination with p21 downregulation will drive the cells down an apoptotic pathway rather than cell cycle arrest or senescence. 92 Also appealing regarding p21 knockdown is the observed exhaustion of normal stem cells in the absence of p21, 29 such that a cancer-targeted cellular stress may be amplified in the cancer stem cell compartment by decreased p21 expression.
Antisense oligonucleotides of p27 mRNA were shown to be able to augment the retroviral integration into human primitive hematopoietic cells as assessed in the NOD/SCID model. 51 Forced overexpression of p27 has been shown to induce apoptosis in brain 93 and breast 94 tumor cells. p27 is also targeted for degradation by SCF complex containing skp2 and knocking down levels of skp2 by either siRNA or antibodies was shown to increase p27 levels and limit cell proliferation in multiple tumor types. [95] [96] [97] A degradation-resistant p27 mutant, p27T187A, can limit the progression of intestinal tumors by limiting carcinoma formation from adenomatous lesions. 98 Targeting the CIP/KIP family of CKIs by gene therapy approaches may thus be a reasonable approach to regulate stem cell activity.
Concluding remarks
The field of adult stem cell biology has increased dramatically following the immunophenotypical purification of mouse HSCs in the late 1980s. Only recently have similar flow cytometric techniques and classical stem cell assays been employed to characterize cancer stem cells from nonhematopoietic tissues. Further investigations are needed to fully determine the cell cycle status and dynamics within these cells. If they are shown to be highly similar to those of normal stem cells, the underlying question may be to what end these molecules can be targeted for a therapeutic goal. That is to say can normal stem cells be expanded without generating a malignant phenotype and cancer stem cells induced to undergo apoptosis without destroying the regenerative capacity of the normal tissue. This goal can be achieved only when the distinct roles of CKIs and other relevant boundary molecules in normal stem cells as opposed to cancer stem cells are defined. 17 It would be prudent then to consider the CKIs as molecular brakes hinging upon upstream signaling molecules, such as is the case with Bmi-1 and p21 49 or MAD1 and p27. 53 Thus, future studies of the cell cycle kinetics must also take account the roles of these and other signaling molecules, as alterations in their function may ultimately affect the cell cycle profile. Given the compelling evidence for the roles in stem cells, and the molecular basis for their actions, CKIs may provide a unique set of targets for developing stem cell therapeutics.
